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ORIGINAL ARTICLEWhole Genome Methylation Analysis of Nondysplastic Barrett
sses to Invasive CancerEsophagus that ProgreMark P. Dilworth, FRCS(Gen), Tom Nieto, MRCS, Jo D. Stockton, PhD, Celina M. Whalley, MSc,
Louise Tee, MSc, Jonathan D. James, PhD, Fergus Noble, MRCS, Tim J. Underwood, FRCS(Gen),
Michael T. Hallissey, FRCS,y Rahul Hejmadi, FRCPath, Nigel Trudgill, FRCP,z
Olga Tucker, FRCS,§ and Andrew D. Beggs, FRCS(Gen) PhD yObjective: To investigate differences in methylation between patients with
nondysplastic Barrett esophagus who progress to invasive adenocarcinoma
and those who do not.
Background: Identifying patients with nondysplastic Barrett esophagus who
progress to invasive adenocarcinoma remains a challenge. Previous studies have
demonstrated the potential utility of epigeneticmarkers for identifying this group.
Methods: A whole genome methylation interrogation using the Illumina
HumanMethylation 450 array of patients with nondysplastic Barrett esopha-
gus who either develop adenocarcinoma or remain static, with validation of
findings by bisulfite pyrosequencing.
Results: In all, 12 patients with ‘‘progressive’’ versus 12 with ‘‘nonprogres-
sive’’ nondysplastic Barrett esophagus were analyzed via methylation array.
Forty-four methylation markers were identified that may be able to discrimi-
nate between nondysplastic Barrett esophagus that either progress to adeno-
carcinoma or remain static. Hypomethylation of the recently identified tumor
suppressor OR3A4 (probe cg09890332) validated in a separate cohort of
samples (median methylation in progressors 67.8% vs 96.7% in nonprog-
ressors; P ¼ 0.0001, z ¼ 3.85, Wilcoxon rank-sum test) and was associated
with the progression to adenocarcinoma. There were no differences in copy
number between the 2 groups, but a global trend towards hypomethylation in
the progressor group was observed.
Conclusion: Hypomethylation of OR3A4 has the ability to risk stratify the
patient with nondysplastic Barrett esophagus and may form the basis of a
future surveillance program.
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Annals of Surgery  Volume 269, Number 3, March 2019sophageal adenocarcinoma (EADC) incidence is increasing1 andE currently represents 5% of the digestive tract cancers in the UK.2
Overall disease survival is poor,3 but correlates with stage of cancer
at presentation, demonstrating significant survival advantages with
detection of early-stage disease.4,5
Barrett esophagus (BE), in which normal squamous mucosa is
replaced with a metaplastic columnar phenotype, results from pro-
longed exposure to stomach acids and bile salts, which reflux into the
esophagus causing chronic inflammation and tissue damage.6
The incidence of BE is increasing, largely thought to be a
consequence of obesity-induced reflux disease.7–10 BE is associated
with an increased risk of EADC,11 but for the majority of patients, BE
will never progress beyond simple benign metaplasia.12,13 However,
in a small number of patients, dysplasia will develop, with some
progressing to EADC.14 The incidence of EADC in the BE popula-
tion is up to 150 times greater than unaffected individuals.12
Although the pathological changes seen in Barrett adenocar-
cinoma are understood as part of a well-established metaplasia-
dysplasia-carcinoma sequence,15 the molecular drivers are less
clear.16–18 The current dilemma is that for patients with nondys-
plastic BE, there are no accurate methods for identifying the small
number of patients at high risk of progression to cancer.
Surveillance practice of the Barrett patients varies widely,
between some who endoscope patients each year in contrast to others
who will never repeat the investigation.19 The ongoing UK Medical
Research Council funded BOSS study aims to understanding the
optimum surveillance strategy, randomizing between prospective
monitoring BE patients with frequent endoscopic assessment or a
‘‘watch and wait’’ policy.20
Clearly, there is need for a method of risk stratification in these
patients to facilitate a streamlined surveillance program by identify-
ing high-risk nondysplastic BE patients. Attempts at biomarker
development for stratification of high-risk BE have focused on
mutational change, specifically around the role of TP53 mutation
in predicting ‘‘high-risk’’ disease,21 given its role as a driver in
esophageal cancer. However, Ross-Innes et al17 have convincingly
demonstrated the presence of pathogenic TP53 mutations in appar-
ently normal squamous esophageal mucosa, thus making its role in
progression to invasive adenocarcinoma unclear. However, the role
of epigenetic change in the pathogenesis of BE and esophageal
cancer is less well-understood, but may well happen much earlier in
the cancer development pathway, and, as a direct result, provide a
more appropriate target for both predicting its development and
potentially arresting tumorigenesis, should a suitable epigenetic
modulator be identified.
Multiple methylation markers have been identified which can
discriminate between high-risk and low-risk BE including APC/
p16,22 MGMT,23 PKP-1,24 TIMP3/TERT,25 RUNX3/HPP1,26,27 and
AKAP12.28 Agarwal et al29 performed a MeCIP array-based
approach to compare the methylomes of progressor (n ¼ 5) versus
nonprogressing patients (n ¼ 4). In patients who progressed to
invasive adenocarcinoma, their original biopsies began either with
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comparison difficult. However, subsequent analysis of the top 25
differential methylation patterns found 3 gene regions with hyper-
methylation amongst the progression group (Pro_MMD2,
Pro_ZNF358, and Intra_F10), with a trend towards global hypo-
methylation, in keeping with other epithelial premalignant con-
ditions.30 Kaz et al31 also found significant differences in
methylation in patients with BE due to factors such as obesity,
smoking, and sex, which may be responsible for some of the
observed risk.
While the studies reviewed do show variation in methylation
between progressive versus nonprogressive BE, the methodology has
been heterogeneous, and few have conducted the study with a group
of the same patients tracked over time.
The study aims to determine whether there are differences in
methylation in patients between high-risk nondysplastic BE, which
will progress to cancer, versus low-risk BE.
METHODS
Patients and Samples
Two sample cohorts were identified containing patients who
either progressed to EADC from nondysplastic BE or remained with
nondysplastic BE (NDBE) identified from a prospectively main-
tained database of patients with BE at a large district general
hospital. Inclusion criteria for the study were progressing patients
with nondysplastic BE who, when observed over the study period,
developed EADC. Samples were only included where there was a
NDBE biopsy and then histology evidence that the patient devel-
oped adenocarcinoma. Nonprogressing patients were identified
from a biopsy of NDBE, which, when followed over time, never
progressed beyond NDBE. To be included in this group, the patient
must have been in a surveillance program for a minimum of 15 years
and have serial biopsies over that period. Patients within the
surveillance program had endoscopy and biopsy every 2 years.32
Biopsies were taken at the time of the initial surveillance endoscopy
and at all subsequent endoscopies including immediately before
treatment as part of their staging. They were also required to have
still been alive and to have had a NDBE biopsy within 2 years of
this study.
Patients were excluded from the study if BE material was only
available as part of tumor-associated BE or if dysplasia was identi-
fied in any BE biopsies.
All tissue used was formalin-fixed paraffin-embedded (FFPE)
samples obtained from pathology libraries and prepared by the
University of Birmingham Human Biomaterials Resource Centre
(ethical approval 09/H1010/75). H&E stained slides were reviewed
by a consultant pathologist to ensure that the samples were BE and
had no dysplasia throughout their extent. Cut 5-mM paraffin sections
were mounted onto frosted slides, and macrodissection for BE was
carried out. DNA extraction was then performed using Qiagen
DNeasy Blood and Tissue kit following the manufacturer’s protocol.
Each sample of extracted DNAwas then quantified and qualified by
Nanodrop spectrophotometry and Qubit fluorimetry. Bisulfite con-
version was performed using a Zymo DNA methylation bisulfite
conversion kit following the modified Illumina Infinium protocol on
500 ng of extracted DNA.
Methylation Arrays
The Illumina HumanMethylation 450 array, in which the
methylation status of more than 485,000 individual CpG sites are
examined,33 was used to compare sample groups (progressing
NDBE vs nonprogressing NDBE). Once bisulfite converted, 1 ng
of DNA was quality-controlled (Illumina FFPE QC kit) with only
480 | www.annalsofsurgery.comsamples with dCt <5 being taken forward to array analysis. The
resulting samples underwent repair suitable for array hybridization
using the Illumina FPPE restore kit,34 followed by hybridization
to Illumina HumanMethylation450 arrays using manufacturer’s
protocols and scanned on an Illumina iScan. Normalized intensity
files (iDAT) were exported using GenomeStudio for downstream
analysis.
Immunohistochemistry
Immunohistochemistry (IHC) was carried out on a Leica Bond
RX system using a mouse polyclonal anti-OR3A4 antibody (Abcam
ab67107) at a dilution of 1:100 with a primary incubation time of
15 minutes.
Immunohistochemistry was scored on epithelial and stromal
components and a composite score consisting of the sum of expres-
sion within membranous, nuclear and cytoplasmic compartments on
a score of 1 to 4 was made, giving a combined maximum possible
score of 12 for each compartment. Scoring was carried out by 2
independent observers blinded to progressor/nonprogressor status.
Bioinformatics Analysis of Array Data
Bioinformatics analysis of the methylation microarrays was
carried using the ChAMP package35 via Bioconductor/R. In brief,
red/green intensity values were captured from Illumina iDAT files,
background-corrected and SWAN-normalized to produce M values
(further details given in supplementary methods, http://links.
lww.com/SLA/B376).
M values were analyzed using a logistic regression model
using Empirical Bayesian shrinkage of moderated t-statistics to
correct for small sample size. Small sample size was controlled
for by setting stringent false discovery rate Q values of <0.05.
Identification of variable methylated sites allowed the CpG site
markers to be highlighted. DNA copy number analysis was carried
out using the DNAcopy module of ChAMP.
Pyrosequencing Validation of Hits
Methylation-insensitive primers were designed and sourced,
using Qiagen PyroMark Primer Design software v2.0. Primers were
designed to flank CpG sites of interest. Illumina CG methylation
probe locations were retrieved from the UCSC genome browser,36
and Fast-All sequence retrieved for200 bp toþ200 bp of the target
CG dinucleotide. Primer design settings were optimized to design
amplicons suitable for FFPE pyrosequencing, with the optimum
amplicon size set to between 80 and 150 bp. All other settings
were as per the standard Qiagen design parameters. Primers were
ordered from Sigma-Aldrich, with the biotinylated pyrosequencing
primer being purified by high-performance liquid chromatography
and the remainder by desalting. Pyrosequencing PCR was performed
using Qiagen PyroMark PCR Gold kit, consisting of 2mL of bisul-
fite-converted DNA, 25mL of PCR master mix, 5mL of CoralLoad
dye, 3mL MgSO4, 10mL of Q reagent, and 2.5mL each of forward
(20mM) and reverse (20mM) primer. Reaction conditions were
determined experimentally by use of a gradient PCR for each
primer pair. A typical reaction consisted of activation at 95C
for 15 minutes, followed by 45 cycles of denaturation at 948C for
30 seconds, annealing at 568C for 30 seconds, and extension at 728C
for 30 seconds, followed by a final extension step at 728C for
10 minutes. In addition to experimental DNA, each PCR was
performed with 100% methylated DNA, 100% unmethylated
DNA, and ddH2O as controls. Methylated and unmethylated
DNAwas generated in house by means of M.SSl conversion (meth-
ylated DNA) and whole genome amplification using the Qiagen
Repli-G kit (unmethylated DNA). Primer sequences for validation
pyrosequencing were as follows: for FGFR2 cg17337672 these were
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
TABLE 1. Top 20 Array-identified CpG Sites With Methylation Variation Between Nondysplastic Samples Which Progress to
EADC Versus Those Which Remain Static
Probe ID t P Adj. P Gene Name
cg09890332 12.26 2.02E-08 0.0031 OR3A4
cg24007926 11.05 6.84E-08 0.0032 NA
cg17337672 10.95 7.54E-08 0.0032 FGFR2
cg02226469 10.88 8.17E-08 0.0032 NA
cg17433294 10.51 1.22E-07 0.0038 NMUR2
cg18479711 10.31 1.52E-07 0.0039 HDAC4
cg09011162 10.15 1.82E-07 0.0040 LMF1
cg19733463 9.83 2.61E-07 0.0045 NMUR1
cg16150571 9.64 3.26E-07 0.0045 SNORD116-22
cg24424217 9.62 3.35E-07 0.0045 ZNF511
cg13164993 9.57 3.52E-07 0.0045 RBP3
cg14019464 9.53 3.70E-07 0.0045 TRIB3
cg24581378 9.53 3.71E-07 0.0045 ZAP70
cg05230642 9.36 4.54E-07 0.0051 SNORD115-14
cg12297814 9.26 5.08E-07 0.0052 IGFN1
cg11231240 9.23 5.33E-07 0.0052 NA
cg11864327 8.96 7.40E-07 0.0063 ZFP2
cg16771467 8.92 7.78E-07 0.0063 ATP8B1
cg17304276 8.88 8.14E-07 0.0063 CUX2
cg11443888 8.86 8.36E-07 0.0063 TMEM151B
Probe ID: the Illumina cg probe ID from the Illumina manifest; T: the t value (the size of the difference relative to the variation in the sample).
P¼ the raw P value, not corrected for multiple testing; adjusted P¼ the P value corrected for multiple testing.
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TCAATCTTCCCCCAAACAACCACT, and sequencing ¼ GTTTA-
GAAGTTTTTTTTGGATTAGT; for ORA3A4 cg07863524 these
were forward ¼ GTGGTAGAAGTAGGATGAGGTGTTGATAAT,
reverse¼ [Btn]CTTCAACTTCCTTCCCCTTACATTT, and sequenc-
ing ¼ GGGTAGGGATGGAAGA; for OR3A4 cg09890332 these
were forward ¼ TTAAAGTGTTAGGATTATAGGTGTGAGTTA,
reverse ¼ [Btn]TTTCCCAACCCTAATCACTACTAATAAAAT,
and sequencing ¼ GGATTATAGGTGTGAGTTAT.
RESULTS
Patient Selection
In all, 67 patients were recruited—37 from Sandwell andWest
Birmingham NHS Trust (SWBNT) and 30 from University Hospital
Birmingham NHS Trust (UHBFT). Of these, 20/67 progressed from
nondysplastic BE and 47 did not. The age range was between 42 and
60 years, with a median age of 56 years, of which 60/67 (89.6%) were
male. The median time to diagnosis of EADC in ‘‘progressor’’
patients was 114 months, with a range of 14–162 months. Of the
patients recruited, in the SWBNT group, 6 progressors and 6 non-
progressors, and in the UHBFT, 6 progressors and 6 nonprogressors
were taken forward to methylation array analysis, giving a total of 12
progressors and 12 nonprogressors. This samples size was chosen
because of our previous experience with biomarker discovery in
methylation arrays as a suitable size for biomarker discovery. A
validation cohort of 32 patients (progressors 18, nonprogressors 14)
were obtained from University Hospital Southampton. All patients
included in the study had symptoms of reflux disease as a presenting
symptom. For all patients in the progressor cohort (n ¼ 30), the
observed pathological disease stages at the time of resection were
high-grade dysplasia (4/30, 13%), T1N0 (10/30, 33%), T1N1 (1/30,
3%), T2N0 (2/30, 7%), T2N1 (3/30,10%), T3N0 (6/30, 20%), and
T3N1 (4/30, 13%). All patients with high-grade dysplasia underwent
endoscopic mucosal resection and the remainder underwent
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.esophagectomy. All patients recruited had validation pyrosequencing
performed.
Methylation Microarray Analysis
Twenty-four samples in total were hybridized successfully
to Illumina HumanMethylation450 microarrays. All arrays
passed manufacturers QC as specified by metrics in Illumina
GenomeStudio. Differential methylation analysis at the probe level
(Table 1) revealed significant differences in methylation between
progressor and nonprogressors in nondysplastic BE (Fig. 1). In all,
44 significantly [defined as Bayes factor (BF) >5, chosen as it is
equivalent to a genome, wide P value significance of 1 106]
differentially methylated targets were identified, the bulk being hypo-
methylated,with a trend towards global hypomethylation in progressor
samples as demonstrated by left-shift of the Volcano plot (Fig. 1).
Differential Methylation at the Probe Level
The top ranked differentially methylated probe was
cg09890332 (chr17:3212495–3212495, hg19 coordinates), which
tags a CpG dinucleotide 1044 bp upstream of the transcription
start site of the long noncoding RNA, OR3A4 (NRR_024128.1). The
second highest ranked differentially methylated probe was
cg24007926 (chr2:206842761–206842761, hg19 coordinates). This
CpG dinucleotide is within a large, intragenic region, with the nearest
gene being INO80D (INO80 complex subunit D, NM_017759.4),
15,684 bp downstream of this CpG. The third highest ranked differ-
entially methylated probe was cg17337672 (chr10:123354172–
123354172), which tags a CpG dinucleotide within intron 2 of
FGFR2 (fibroblast growth factor receptor 2, NM_000141.4).
Differentially methylated regions (DMRs) were called
between progressors and nonprogressors via the dmrLasso function
of the CHAMP software package (Table 2). Significant DMRs were
found from chr2:503065–503193 (which tags an intragenic region,
DMR P¼ 7.69 104), chr5:8217236–8217322 (which also tags an
3intragenic region, DMR P ¼ 1.27 10 ), and chr10: 123353418–
www.annalsofsurgery.com | 481
FIGURE 1. Volcano plot of probe-level methylation in progres-
sors versus nonprogressors. Blue points ¼ Bayes factor <5; red
points ¼ Bayes factor >5. The plot shows a leftward shift of
probes towards the left, suggesting global hypomethylation.
Dilworth et al Annals of Surgery  Volume 269, Number 3, March 2019123355576, which spans a region from the 5’-UTR of FGFR2 to the
first exon within FGFR2 (DMR P ¼ 4.79 103).
We took advantage of the information provided by the 2 color
Illumina Infinium chemistry to call copy number aberrations (CANs)
within the regions targeted by the methylation probes using the CNA
calling function of CHAMP. This did not demonstrate any recurrent
copy number alterations between progressors and nonprogressors.
There were no significant differences in the numbers of CNA
between the 2 groups, with a median of 43 CNAs (range 24–92)
in the progressors versus 44 CANs (range 30–52) in the nonprog-
ressors (P ¼ 1.0, Wilcoxon rank-sum).
Pathway methylation analysis was carried out using Database
for Annotation, Visualisation and Integrated Discovery. Initially
Kyoto Encylopedia of Genes & Genomes pathway analysis showed
that genes associated with mitogen-activated protein kinase signaling
were enriched in the dataset (P ¼ 0.012). Gene ontology analysis
using the UP_KEYWORDS feature showed significant enrichment
6for the disease mutation (P ¼ 9.6 10 ), polymorphism (P ¼
TABLE 2. Table of Differentially Methylated Regions (DMRs)
DMR ID Probe ID
Probe Level
Adjusted P Chromosome Gene
1 cg21273584 0.014 2 NA
1 cg00854591 0.045 2 NA
1 cg11573608 0.014 2 NA
2 cg25568703 0.047 5 NA
2 cg25016964 0.039 5 NA
2 cg17642708 0.021 5 NA
3 cg10788901 0.172 10 FGFR2
3 cg14856220 0.044 10 FGFR2
3 cg17337672 0.003 10 FGFR2
3 cg02412684 0.031 10 FGFR2
3 cg06791446 0.058 10 FGFR2
3 cg22633036 0.581 10 FGFR2
482 | www.annalsofsurgery.com1.7 105), glycoprotein (P¼ 3.4 105), and alternate splicing (P
¼ 1.1 104) terms.
Validation Pyrosequencing
Because of the likely biological relevance of FGFR2, and the
data demonstrating that OR3A4 was the top differentially methylated
CpG, validation pyrosequencing was carried out on all 67 patients.
Normality of distribution of methylation values was ascertained by
histogram plots, in which it was found that methylation was non-
normally distributed; therefore nonparametric testing was carried out.
For OR3A4 cg09890332, median methylation was 67.8%
[interquartile range (IQR) 12.1] in progressors versus 96.7% (IQR
16.1) in nonprogressors (P¼ 0.0001, z¼ 5.158; Wilcoxon rank-sum
test) (Fig. 2). The pyrosequencing assay design used covered 2
additional CpG þ4 bp and þ10 bp downstream of cg09890332.
Median methylation in these was 66.8% and 59.7% in progressors
versus 75.0% and 68.1% in nonprogressors (P ¼ 0.0280 and 0.0368,
z ¼ 2.197 and 2.088, Wilcoxon rank-sum test). To investigate
whether this phenomenon was localized to this region or was a
gene-wide phenomenon, an additional pyrosequencing assay was
designed based on probe ID cg07863524 (chr17:3213471–
3213471), which is þ976 bp downstream from cg09890332 and
68 bp from the transcription start site of OR4A4. This demonstrated
that median methylation was 62.2% in progressors and 56.7% in
nonprogressors (P¼ 0.600, z¼0.524; Wilcoxon rank-sum test). A
temporal analysis of change in methylation of cg09890332 over time
is shown in Fig. 3, showing that the difference between methylation
levels at initial biopsy is static between progressors and nonprog-
ressors, and that the difference is maintained over time and is
detectable for an extended period of time before diagnosis of EADC.
We then validated cg17337672 within FGFR2, finding that
median methylation was 83.4% in progressors versus 82.2% in
nonprogressors (P ¼ 0.51, z ¼ 0.653; Wilcoxon rank-sum test).
Expression of OR3A4 in Progressors Versus
Nonprogressors
We then carried out immunohistochemical assessment of
expression of OR3A4 (Fig. 4), which, although is labeled as long
noncoding RNA, is actually expressed in tissues (see Supplementary
results, http://links.lww.com/SLA/B376), in a subset of 12 patients.
For the stromal compartment, amedian expression of 6 (IQR 4–7)was
seen in progressors and 2 (IQR 1–3) in nonprogressors (Wilcoxon
rank-sum P¼ 0.0308, z¼2.160). For the epithelial compartment, a
median expression of 8 (IQR 8–10) was seen in progressors and 5.5
(IQR 3–10) in nonprogressors (Wilcoxon rank-sum P ¼ 0.4587, z ¼
0.741). Percentage methylation at OR3A4 and stromal expression
Start of
DMR (bp)
End of
DMR (bp)
Size
in bp
Change in
Methylation
P for
DMR
502999 503195 197 34% 7.69E-04
502999 503195 197 16% 7.69E-04
502999 503195 197 27% 7.69E-04
8216903 8217655 753 25% 1.27E-03
8216903 8217655 753 22% 1.27E-03
8216903 8217655 753 33% 1.27E-03
123352704 123355661 2958 27% 4.79E-03
123352704 123355661 2958 24% 4.79E-03
123352704 123355661 2958 47% 4.79E-03
123352704 123355661 2958 38% 4.79E-03
123352704 123355661 2958 13% 4.79E-03
123352704 123355661 2958 4% 4.79E-03
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
FIGURE 2. Box plot of OR3A4methylation differentiating high-
risk nondysplastic BE.
Annals of Surgery  Volume 269, Number 3, March 2019 Epigenetics of Barrett Oesophaguswas strongly negatively correlated (Pearson correlation coefficient
0.85, P ¼ 0.014), and a similar, but nonsignificant correlation was
observed with epithelial expression and methylation at OR3A4 (Pear-
son correlation coefficient 0.40, P ¼ 0.373).
Ability of OR3A4 Methylation to Act as a
Discriminator in BE
To understand the accuracy of using methylation within
cg09890332 of OR3A4 as a biomarker for high-risk BE, we carried
out a multivariable reverse stepwise logistic regression analysis of
methylation at the 3 tagged CpG dinucleotides within the pyrose-
quencing assay as the independent variables and progressor versus
nonprogressor status as the dependent variables. In this model, CpGs
2 and 3 became nonsignificant (P ¼ 0.3325 and P ¼ 0.4764) and
were removed from the model, leaving the first CpG in cg09890332
as being significant [coef ¼ 0.0563, SE ¼ 0.016, z ¼ 3.40, P ¼
0.001, 95% confidence interval (CI) 0.089 to 0.024]. Using
receiver-operator curve modeling, the area under curve of this model
was 0.82 (95% CI 0.80–0.83) in the cohort where the marker was
originally generated (Supplementary Fig. 2, http://links.lww.com/
SLA/B376).
FIGURE 3. Change in methylation across temporally acquired
samples for OR3A4. The y-axis shows percentage methylation
at cg09890332 as observed by pyrosequencing. Time-points
on the x-axis refer to the sampling points, with 1 representing
the initial baseline endoscopy and subsequent visits referred by
increasing numbers (surveillance intervals are variable).
FIGURE 4. Light micrographs of representative examples of
expression of OR3A4 via IHC of nonprogressor (A 10 view, B
40 view) and progressor (C 10 view, D 40) view.
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.We then used the diagt function of Stata 11.2 to model a set
methylation threshold effect on sensitivity and specificity of the test,
aiming for maximum negative predictive value and correcting for an
incidence rate within the cohort of 0.7%. Modeling at a threshold of
below 89% being significant showed that hypomethylation at
OR3A4 can predict progression to invasive carcinoma with a sensi-
tivity of 70.8%, specificity of 86%, positive predictive value of 85%
and negative predictive value of 72.5%.
We then carried out validation bisulfite pyrosequencing on a
cohort of progressors (n ¼ 18) versus nonprogressors (n ¼ 14,
Southampton cohort), finding that there were significant differences
(P ¼ 0.0477, unpaired t test) in methylation, with an average
methylation of 59.2% (95% CI 56.2%–62.1%) in progressors versus
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model demonstrated area under curve 0.70, and adjustment for a
prevalence of 0.7% using a threshold of 58% demonstrated a
sensitivity of 33.3%, specificity of 78.6%, positive predictive value
of 10.5%, and negative predictive value of 94%.
CONCLUSIONS
We have identified that hypomethylation at cg09890332
corresponding to the CG nucleotide at position (CHR) of OR3A4
can discriminate between patients who progress from nondysplastic
BE and those who did not. This association is maintained across
independent cohorts, and seems to be related temporally (ie, the
association is maintained in the earliest set of samples from a time
series of follow-up biopsies in patients with BE), and also by case
status. Gastroesophageal reflux is a key risk factor in the develop-
ment of BE,19 and also obesity and cigarette smoking.
The effect of hypomethylation on theOR3A4 gene seems to be
functional, in that immunohistochemistry reveals an increase in
OR3A4 expression in samples with hypomethylation. The finding that
the stromal expression, in particular, is increased is of interest, given
the known effect of ‘‘pathological’’ stroma in the pathogenesis of
esophageal cancer.37 Our observed region coincides within 225 bp of a
CTCF and RAD21 transcription factor binding site, further suggesting
that methylation there has a functional effect to prevent transcription
factor binding and alter gene expression. Guo et al38 performed a
genome-wide screen of long noncoding RNAs in gastric adenocarci-
noma, finding thatOR3A4was significantly (55.9-fold) overexpressed
in these patients. They also observed that levels of OR3A4 were
correlated with metastatic potential and prognosis. Furthermore, they
utilized OR3A4 overexpression vectors and performed siRNA knock-
down to demonstrate that OR3A4 seems to regulate cellular prolifera-
tion in gastric cancer cell lines. Finally, they utilized their
overexpressing cell line models and implanted them into nude mice,
finding that OR3A4 overexpressing gastric cancer cell lines grew
significantly faster and more aggressively than with knockdown of
OR3A4. Downstream analysis of target genes demonstrated that
OR3A4 targets PDLIM2, a putative tumor suppressor than regulates
cell cycle and adhesion; PIWIL1, a transcriptional silencer; andDLX4
which induces epithelial-mesenchymal transition via TWIST1.
We found both at the individual probe level and as part of a
DMR that there is hypomethylation in the CpG island associated with
FGFR2; however, this did not validate at the single probe level when
examined with bisulfite pyrosequencing. FGFR2 has been observed
to undergo recurrent alteration in both esophageal adenocarcinoma39
and squamous cell carcinoma,40 with the latter demonstrating recur-
rent amplification. The disparity between our microarray results and
validation by pyrosequencing may be due to probe inflation caused
by small sample size, and is a significant weakness of our study;
however, given its biological associations with esophageal adeno-
carcinoma, further work is needed.
In common with premalignant lesions in cancer, such as
colorectal adenomatous polyps,30 we observed a trend towards
genome-wide hypomethylation as demonstrated by a leftward shift
of our genome-wide volcano plot, suggesting a widespread over-
expression of genes as part of the development towards malignancy.
We also found no difference in chromosomal instability between
progressors and nonprogressors, although there was widespread
instability within both sets of samples, in common with what has
previously been observed41 in BE.
Another weakness of our study was the inability to carry out a
more comprehensive validation of all observed markers as part of a
larger panel of markers. Our study made use of extremely small
tissue biopsies from endoscopic surveillance programs, which
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these samples and used for downstream validation, and thus valida-
tion of the observed DMR and other differentially methylated
position regions could not be carried out. We were also limited in
the number of samples that could be tested, because of the rarity of
biopsy samples before the diagnosis of esophageal cancer, as we took
advantage of a local screening program to obtain samples. However,
in both the genome-wide and in the validation phase, we believe we
have sufficient power to detect methylation changes in this marker. In
the genome-wide phase, our sample size of 24 patients would allow
us to detect a methylation difference42 of 2%, with a statistical power
of 90%. Similarly, in the validation phase, our sample size would
allow us to detect a minimum methylation change of 10% in the
sample set, given the previously observed median methylation and
standard deviation in these samples.
We observed a median time to diagnosis of esophageal
adenocarcinoma on commencement of the surveillance program
of 114 months, which we believe is a reflection of the early
identification of these patients and their enrolment into a screening
program, and the known slow progression of esophageal adenocar-
cinoma. A further problem with molecular genetic analysis is
heterogeneity, due to the low proportion of cells within a biopsy
specimen that contain changes compatible with BE, which leads to
less clear methylation changes.
Hypomethylation of OR3A4, although seemingly accurate for
the detection of progression of Barrett to invasive adenocarcinoma, is
likely to be of more utility as a multimodal stratifier in BE, taking
account of previous findings at the mutational and copy number level,
and also epigenetic change. However, for the purpose of designing a
surveillance program with the ability to risk-stratify the nondysplastic
BE patient, this marker has significant potential utility.
Development of a streamlined surveillance program could
lead to cost savings through the avoidance of unnecessary upper
gastrointestinal endoscopy or via a less invasive technology such as
the CytoSponge,43 in a low-risk cohort identified by a molecular
marker panel. More frequent endoscopy in the high-risk cohort could
lead to earlier diagnosis of EADC or initiate management of BE to
arrest further progression. In conclusion, development of a stratified
marker panel in the context of a clinical trial is now needed to
improve diagnosis of high-risk BE.
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